{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:35:33Z","timestamp":1790534133801,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020875","name":"Universite Versailles Saint-Quentin-en-Yvelines","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omtn.2022.11.017","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:54:38Z","timestamp":1669031678000},"page":"606-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice"],"prefix":"10.1016","volume":"30","author":[{"given":"Flavien","family":"Bizot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remko","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tensorer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Dmitriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Spitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-1165","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Goyenvalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.11.017_bib1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative therapeutic approaches for duchenne muscular dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtn.2022.11.017_bib2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2022.11.017_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2022.11.017_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2022.11.017_bib5","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2022.11.017_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1126\/science.aba4515","article-title":"RNA-targeted drugs for neuromuscular diseases","volume":"371","author":"Ferlini","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omtn.2022.11.017_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2022.11.017_bib24","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.11.017_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2022.11.017_bib9","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.3347839","article-title":"Expression of the murine Duchenne muscular dystrophy gene in muscle and brain","volume":"239","author":"Chamberlain","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.omtn.2022.11.017_bib10","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1073\/pnas.192571199","article-title":"Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle","volume":"99","author":"Haslett","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.11.017_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molcel.2005.08.012","article-title":"Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements","volume":"20","author":"Gehring","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2022.11.017_bib12","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.11.017_bib13","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.omtn.2022.11.017_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/24.15.3059","article-title":"Stability of the human dystrophin transcript in muscle","volume":"24","author":"Tennyson","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2022.11.017_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.omtn.2022.11.017_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2022.11.017_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2022.11.017_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2353\/ajpath.2009.080537","article-title":"Valproic acid activates the PI3K\/Akt\/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy","volume":"174","author":"Gurpur","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2022.11.017_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2018-07-863233","article-title":"Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice","volume":"133","author":"Daenthanasanmak","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2022.11.017_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-018-0180-z","article-title":"Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone","volume":"8","author":"Iskenderian","year":"2018","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2022.11.017_bib21","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1093\/hmg\/ddv214","article-title":"Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies","volume":"24","author":"Rouillon","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2022.11.017_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","article-title":"Evaluating the impact of variable phosphorothioate content in tricyclo-DNA antisense oligonucleotides in a duchenne muscular dystrophy mouse model","volume":"29","author":"Echevarr\u00eda","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2022.11.017_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in\u00a0situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2022.11.017_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2010.07.008","article-title":"MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin\/nNOS pathway","volume":"12","author":"Cacchiarelli","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2022.11.017_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41419-021-03936-w","article-title":"Valproic acid stimulates myogenesis in pluripotent stem cell-derived mesodermal progenitors in a NOTCH-dependent manner","volume":"12","author":"Breuls","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2022.11.017_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1534-5807(04)00107-8","article-title":"Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin","volume":"6","author":"Iezzi","year":"2004","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2022.11.017_bib28","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1073\/pnas.0810666106","article-title":"Neuronal cell depolarization induces intragenic chromatin modifications affecting NCAM alternative splicing","volume":"106","author":"Schor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.11.017_bib29","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.jmb.2016.04.017","article-title":"Coupling of RNA polymerase II transcription elongation with pre-mRNA splicing","volume":"428","author":"Saldi","year":"2016","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omtn.2022.11.017_bib30","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.cell.2022.04.031","article-title":"Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy","volume":"185","author":"Marasco","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2022.11.017_bib31","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202254721","article-title":"Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors","volume":"23","author":"Consalvi","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2022.11.017_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in duchenne muscular dystrophy mouse model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.11.017_bib33","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative antisense screening and optimization for exon 51 skipping in duchenne muscular dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.11.017_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2022.11.017_bib35","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/brain\/aww011","article-title":"Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in\u00a0vitro proof of concept","volume":"139","author":"Rutten","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2022.11.017_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nprot.2006.27","article-title":"Protocol for the fast chromatin immunoprecipitation (ChIP) method","volume":"1","author":"Nelson","year":"2006","journal-title":"Nat. Protoc."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122003092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122003092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:32:37Z","timestamp":1761874357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122003092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"alternative-id":["S2162253122003092"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.11.017","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}